Filing Details
- Accession Number:
- 0001209191-21-024126
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-04-01 16:47:44
- Reporting Period:
- 2021-03-31
- Accepted Time:
- 2021-04-01 16:47:44
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1714899 | Denali Therapeutics Inc. | DNLI | () | 4 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1197020 | L Vicki Sato | C/O Denali Therapeutics Inc. 161 Oyster Point Blvd. South San Francisco CA 94080 | Yes | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2021-03-31 | 18 | $54.38 | 139,069 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2021-03-31 | 877 | $55.91 | 138,192 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2021-03-31 | 635 | $56.92 | 137,557 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2021-03-31 | 136 | $57.61 | 137,421 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Footnotes
- The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan.
- Includes 3,253 restricted stock units.
- The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $55.485 to $56.34 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
- The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $56.52 to $57.405 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
- The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $57.525 to $57.68 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
Billionaire Hedge Funds
